Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features

被引:84
作者
Fuller, CE
Schmidt, RE
Roth, KA
Burger, PC
Scheithauer, BW
Banerjee, R
Trinkaus, K
Lytle, R
Perry, A
机构
[1] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Biostat, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA
[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[5] Mayo Clin, Dept Pathol, Rochester, MN USA
关键词
chromosome; 1; 19; EGFR; in situ hybridization; oligoastrocytoma; p16; PTEN;
D O I
10.1093/jnen/62.11.1118
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Gliomas with hybrid oligodendroglial/astrocytic features are diagnostically problematic, and our ability to predict tumor behavior is limited. Some likely represent intermingled mixed oligoastrocytomas (MOAs), though precise diagnostic criteria and specific markers for this lesion are lacking. From the files at Washington University (1987-2000), 155 "ambiguous" glioma/intermingled MOA candidates were independently classified and graded by 5 neuropathologists, with consensus-derived pure oligodendrogliomas and astrocytomas excluded from further study. The 90 remaining cases (grades 11 = 29, 111 = 44, IV = 17) were analyzed by FISH on formalin-fixed, paraffin-embedded sections. Detectable deletions included combined 1p/19q (9%), solitary 19q (22%), PTEN/DMBT1 (26%), and p16 (32%). EGFR amplification was found in 11%. Patients were followed until death (47%) or a median of 3.3 years. Similar to prior glioma series, patient age (p < 0.0001) and tumor grade (p < 0.0001) were strongly associated with survival times. EGFR amplification (p = 0.0007) and deletions of PTEN/DMBT1 (p = 0.016) or p16 (p = 0.014), either individually or as a group (p = 0.04), portended a shorter median survival compared with tumors lacking these alterations. We conclude that 1) distinct genetic subsets are identifiable by FISH in morphologically ambiguous gliomas, and 2) both histological grading and molecular analysis yield prognostically useful information.
引用
收藏
页码:1118 / 1128
页数:11
相关论文
共 54 条
[1]   Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas [J].
Bauman, GS ;
Ino, Y ;
Ueki, K ;
Zlatescu, MC ;
Fisher, BJ ;
Macdonald, DR ;
Stitt, L ;
Louis, DN ;
Cairncross, JG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :825-830
[2]   Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization [J].
Bigner, SH ;
Matthews, MR ;
Rasheed, BKA ;
Wiltshire, RN ;
Friedman, HS ;
Friedman, AH ;
Stenzel, TT ;
Dawes, DM ;
McLendon, RE ;
Bigner, DD .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) :375-386
[3]   Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections [J].
Burger, PC ;
Minn, AY ;
Smith, JS ;
Borell, TJ ;
Jedlicka, AE ;
Huntley, BK ;
Goldthwaite, PT ;
Jenkins, RB ;
Feuerstein, BG .
MODERN PATHOLOGY, 2001, 14 (09) :842-853
[4]   Small cell architecture - A histological equivalent of EGFR amplification in glioblastoma multiforme? [J].
Burger, PC ;
Pearl, DK ;
Aldape, K ;
Yates, AJ ;
Scheithauer, BW ;
Passe, SM ;
Jenkins, RB ;
James, CD .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (11) :1099-1104
[5]  
Burton EC, 2002, CANCER RES, V62, P6205
[6]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[7]   SUCCESSFUL CHEMOTHERAPY FOR RECURRENT MALIGNANT OLIGODENDROGLIOMA [J].
CAIRNCROSS, JG ;
MACDONALD, DR .
ANNALS OF NEUROLOGY, 1988, 23 (04) :360-364
[8]   Investigation of genetic alterations associated with development and adverse outcome in patients with astrocytic tumor [J].
Cianciulli, AM ;
Morace, E ;
Coletta, AM ;
Occhipinti, E ;
Gandolfo, GM ;
Leonardo, G ;
Carapella, CM .
JOURNAL OF NEURO-ONCOLOGY, 2000, 48 (02) :95-101
[9]  
Coons SW, 1997, CANCER, V79, P1381, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO
[10]  
2-W